Journal article
Neurotoxicity in a phase I trial of continuous‐infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer
Head & neck, Vol.18(3), pp.236-241
05/1996
DOI: 10.1002/(SICI)1097-0347(199605/06)18:3<236::AID-HED5>3.0.CO;2-0
PMID: 8860764
Abstract
Background
Both twice daily fractionated radiotherapy and concurrent cisplatin with once‐daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. The objective of this phase I trial was to determine the maximum tolerated dose of cisplatin which could be given as a continuous infusion concurrent with twice‐daily radiotherapy to patients with locally advanced head and neck cancer.
Methods
Patients were treated with radiotherapy at doses of 110 cGy twice daily for 5 days per week to a total dose of 7040–7590 cGy. Concurrent with radiotherapy, patients received continuous‐infusion cisplatin for 5 days per week. Groups of 3–6 patients were treated with doses of 1–3 mg/m2/day.
Results
Central nervous system toxicity became dose‐limiting. At 1 mg/m2, 2 mg/m2, and 3 mg/m2 confusion was observed and one patient had a seizure. At 3 mg/m2, another patient suffered severe sensory and motor neuropathy. Despite bulky tumors, 12 of the 14 patients had an objective response and 3 achieved a complete response.
Conclusions
The combination of twice‐daily fractionated radiotherapy and concurrent cisplatin by continuous infusion is severely toxic and achieves results similar to less toxic programs. It is not recommended for further investigation or therapy. © 1996 John Wiley & Sons, Inc.
Details
- Title: Subtitle
- Neurotoxicity in a phase I trial of continuous‐infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer
- Creators
- Gerald H ClamonLynn BaatzHenry T HoffmanDavid H HusseyMatthew GlascockTimothy M McCullochScott M Graham
- Resource Type
- Journal article
- Publication Details
- Head & neck, Vol.18(3), pp.236-241
- Publisher
- Wiley Subscription Services, Inc., A Wiley Company; New York
- DOI
- 10.1002/(SICI)1097-0347(199605/06)18:3<236::AID-HED5>3.0.CO;2-0
- PMID
- 8860764
- ISSN
- 1043-3074
- eISSN
- 1097-0347
- Number of pages
- 6
- Language
- English
- Date published
- 05/1996
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Radiation Oncology; Neurosurgery; Otolaryngology; Internal Medicine
- Record Identifier
- 9984006419102771
Metrics
21 Record Views